Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-05-22 Report Publication Anno…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2026
Report Publication Announcement Classification · 92% confidence The document is a brief announcement stating that Formycon AG will disclose its quarterly/interim statements on a future date (May 28, 2026) and provides links to access them. It does not contain any substantive financial data or the actual report. Per the “menu vs meal” rule, it is a notice of report publication, not the report itself. This fits the Report Publication Announcement (RPA) category.
2026-05-22 English
Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the publication date for the first quarter 2026 results and inviting investors to a conference call as well as listing upcoming investor conferences. It does not contain actual financial data, an earnings summary, or the full Q1 report itself. It is an announcement of report timing and an investor event rather than the report or transcript. Therefore, it is best classified as a general regulatory/corporate announcement (RNS).
2026-05-21 English
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive and Baiama are now available in the European Union
Regulatory Filings Classification · 15% confidence The document is a corporate press release (EQS News) about product launches (Aflibercept biosimilars Ahzantive and Baiama) and does not contain financial statements, regulatory form certifications, or shareholder voting results. It is not a report publication notice nor a detailed financial report, but a general corporate announcement. Therefore it falls under Regulatory Filings (RNS) as a miscellaneous regulatory announcement.
2026-05-19 English
Formycon AG: Bekanntmachung der Einberufung zur Hauptversammlung am 10.06.2026 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is an announcement of the convocation (Einberufung) of the Annual General Meeting (Hauptversammlung) of Formycon AG scheduled for June 10, 2026. It includes the agenda items for the AGM, such as presentation of the annual financial statements, discharge of board members, election of auditors, approval of the remuneration report, and amendments to the articles of association. The document does not contain the actual annual report or financial statements but rather invites shareholders to the meeting and informs them about the agenda and where the reports can be accessed. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to it. The document length is substantial (15,000 characters), but it is clearly an invitation and agenda notice, not the report itself. Therefore, the correct classification is AGM Information (AGM-R).
2026-05-04 German
Annual financial report 2025
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2025' and contains comprehensive sections including a management interview, financial highlights, a combined management report, consolidated financial statements, and an independent auditor's report. It covers the full fiscal year performance, which aligns with the definition of a 10-K (Annual Report). FY 2025
2026-04-23 English
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
Earnings Release Classification · 85% confidence The document is a detailed press release announcing Formycon AG’s audited consolidated financial results for fiscal year 2025, including revenue, EBITDA, and guidance for 2026, along with commentary from the CEO and CFO and an invitation to a conference call. It summarizes key financial performance figures and outlook rather than providing the full annual report or statutory filings. Such a release fits the definition of an Earnings Release (ER) for annual results, not a full 10-K, Annual Report, or simple publication notice. FY 2025
2026-04-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.